Maravai Lifesciences Holdings (MRVI) EBIT Margin (2020 - 2026)
Maravai Lifesciences Holdings (MRVI) recorded quarterly EBIT Margin of 3.28% in Q1 2026, up 97.22% quarter-over-quarter from 117.91% in Q4 2025, and up 10166.0% on a YoY basis from N/an in Q1 2025.
Maravai Lifesciences Holdings (MRVI) EBIT Margin (2020 - 2026) Analysis & Trends
Maravai Lifesciences Holdings' EBIT Margin history runs 7 years deep, the most recent figure standing at 3.28% for Q1 2026.
- In Q1 2026, EBIT Margin rose 10166.0% year-over-year to 3.28%; the TTM figure through Mar 2026 stood at 82.19% (up 2776.0% YoY), while the FY2025 annual figure was 115.89%, down 2499.0% from the prior year.
- EBIT Margin was 3.28% for Q1 2026 at Maravai Lifesciences Holdings, up from 117.91% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 74.44% in Q2 2022 to a low of 239.93% in Q3 2024.
- Historically, EBIT Margin has averaged 35.81% across 5 years, with a median of 19.36% in 2024.
- The sharpest annual moves came in 2024 and 2025: EBIT Margin sank 21688 bps in 2024, then surged 14137 bps in 2025.
- A 5-year view of EBIT Margin shows it stood at 53.37% in 2022, then slumped by 118 bps to 9.64% in 2023, then sank by 591 bps to 66.66% in 2024, then sank by 77 bps to 117.91% in 2025, then surged by 97 bps to 3.28% in 2026.
- The last three EBIT Margin figures came in at 3.28% (Q1 2026), 117.91% (Q4 2025), and 98.56% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Maravai Lifesciences Holdings | 737.25 Mn | 728.85 Mn | 33.70 Mn | -3.28% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.28% |
| Dec 31, 2025 | -117.91% |
| Sep 30, 2025 | -98.56% |
| Jun 30, 2025 | -139.84% |
| Mar 31, 2025 | -104.93% |
| Dec 31, 2024 | -66.66% |
| Sep 30, 2024 | -239.93% |
| Jun 30, 2024 | -19.36% |
| Mar 31, 2024 | -29.39% |
| Dec 31, 2023 | -9.64% |
| Sep 30, 2023 | -23.06% |
| Jun 30, 2023 | -16.85% |
| Mar 31, 2023 | 3.21% |
| Dec 31, 2022 | 53.37% |
| Sep 30, 2022 | 61.12% |
| Jun 30, 2022 | 74.44% |
| Mar 31, 2022 | 68.51% |
| Dec 31, 2021 | 67.65% |
| Sep 30, 2021 | 75.87% |
| Jun 30, 2021 | 70.50% |